VANCOUVER, British Columbia, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its ...
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD ...
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies ...
VANCOUVER, British Columbia and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical ...
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 – Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results